Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study

References

• Menter A, Bhutani T, Ehst B, et al. Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis. Dermatol Ther (Heidelb). 2022 Jun;12(6):1289–1302.
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332–337. doi: 10.1111/bjd.17689
   PubMed Web of Science ®Google Scholar
• Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26(5):448–459. doi: 10.1016/j.clindermatol.2007.10.026
   PubMed Web of Science ®Google Scholar
• Messina F, Valenti M, Malagoli P, et al. Early predictors of psoriatic arthritis: a Delphi-based consensus from Italian dermatology centers. Ital J Dermatol Venerol. 2022 Jun;157(3):231–234. doi: 10.23736/S2784-8671.21.07203-0
   PubMedGoogle Scholar
• Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J DermatolTreat. 2022 Feb;33(1):261–265.
   Google Scholar
• Kircik L, Fowler J, Weiss J, et al. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: Pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016 Dec;6(4):627–638.
   PubMed Web of Science ®Google Scholar
• Kivelevitch D, Amin S, Menter A. Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date. Clin Cosmet Investig Dermatol. 2019 Apr 24;12: 249–253. 10.2147/CCID.S165040.
   PubMed Web of Science ®Google Scholar
• Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017 Oct;77(4):667–674.
   PubMed Web of Science ®Google Scholar
• Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study. Dermatol Ther. 2019 Sep;32(5):e13006.
   PubMed Web of Science ®Google Scholar
• Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J DermatolTreat. 2017 Jun;28(4):282–287.
   Google Scholar
• Papp KA, Gerdes S, Leonardi CL, et al. Sustained high efficacy and favorable safety over five years in patients with burdensome psoriasis (UNCOVER-1/UNCOVER-2). J Drugs Dermatol. 2021 Aug 1;20(8):880–887. doi: 10.36849/JDD.6101
   PubMed Web of Science ®Google Scholar
• Tsianakas A, Schwichtenberg U, Pierchalla P, et al. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2022 Sep 6;37(1):85–92. doi: 10.1111/jdv.18572
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of Tildrakizumab for the treatment of difficult-to-treat areas: Scalp, Nail. Palmoplantar and genital psoriasis. J Clin Med. 2022 May 7;11(9):2631. doi: 10.3390/jcm11092631
   PubMed Web of Science ®Google Scholar
• Bachelez H, Chih-Ho Hong H, Pinter A, et al. Efficacy and safety of risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials. In Poster presented at: The 27th European Academy of Dermatology and Venereology. Sep 12-16, 2018; Paris, France: Poster P1865.
   Google Scholar
• Elewski B, Rich P, Crowley J, et al. Risankizumab profile in nail, scalp, and palmoplantar psoriasis: efficacy and safety at 52 weeks in an integrated analysis of patients with moderate-to-severe plaque psoriasis. In Poster presented at: The 24 th World Congress of Dermatology. Jun 10-15, 2019; Milan, Italy. Poster 4251.
   Google Scholar
• Elewski B, Rich P, Crowley J, et al. Efficacy and safety of long-term risankizumab treatment for nail, scalp, and palmoplantar psoriasis: an interim analysis from the open-label extension LIMMitless trial. In Poster presented at the 29th European Academy of Dermatology and Venereology Congress. Oct 29-31, 2020; Vienna: EADV Virtual Congress.
   Google Scholar
• Megna M, Cinelli E, Gallo L, et al. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022 Aug;314(6):619–623.
   PubMed Web of Science ®Google Scholar
• Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. doi: 10.1111/dth.15228
   PubMed Web of Science ®Google Scholar
• Ryan C, Menter A, Guenther L, et al. IXORA-Q Study Group. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018 Oct;179(4):844–852. doi: 10.1111/bjd.16736
   PubMed Web of Science ®Google Scholar
• Calianno G, Esposito M, Fidanza R, et al. Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience. Dermatol Ther. 2021 Jul;34(4):e14993.
   PubMed Web of Science ®Google Scholar
• Guenther L, Potts Bleakman A, Weisman J, et al. Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol. 2020 Jan 7;100(1):adv00006. doi: 10.2340/00015555-3353
   PubMed Web of Science ®Google Scholar
• AlMutairi N, Eassa BI. A randomized controlled ixekizumab Vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis. Expert Opin Biol Ther. 2021 Feb;21(2):297–298. doi: 10.1080/14712598.2021.1843629
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Bakirtzi K, Papadimitriou I, et al. A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study. J Eur Acad Dermatol Venereol. 2022 May;36(5):e359–e361.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Dapavo P, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):693–700.
   PubMed Web of Science ®Google Scholar
• Licata G, Danzuso GCL, Fiorella C, et al. Efficacy, safety and patient’s satisfaction for treatment of genital psoriasis with tildrakizumab: a case series and review of literature. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):e916–e918.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Simonacci M. Exclusively genital psoriasis successfully treated with Risankizumab. Dermatol Ther. 2022 Aug;35(8):e15591. doi: 10.1111/dth.15591
   PubMed Web of Science ®Google Scholar
• Janssen-Cilag SPA Observational study on GUselkumab: Effectiveness and Impact on quality of life in NaïVE or bio experienced patients with regional (facial and genital) psoriasis (GULLIVER study). 2022. [cited 2022 Mar 21]. Available from: Vhttps://clinicaltrials.gov
   Google Scholar
• Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J DermatolTreat. 2023;34(1):2199108. doi: 10.1080/09546634.2023.2199108
   Google Scholar
• Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017 Jan;76(1):70–80.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Atzori L, et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opin Biol Ther. 2022 Apr;22(4):547–554.
   PubMed Web of Science ®Google Scholar
• Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: A secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018 Jun 1;154(6):676–683. doi: 10.1001/jamadermatol.2018.0793
   PubMed Web of Science ®Google Scholar
• Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1240–1247.
   PubMed Web of Science ®Google Scholar
• Alajlan AM, Qadoumi TA. Palmoplantar psoriasis successfully treated with risankizumab. Cureus. 2021 Aug 25;13(8):e17434. doi: 10.7759/cureus.17434
   PubMed Web of Science ®Google Scholar